Desiree Jones1, Fengmin Zhao2, Michael J Fisch3, Lynne I Wagner4, Linda J Patrick-Miller5, Charles S Cleeland6, Tito R Mendoza6. 1. Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: Djones1@mdanderson.org. 2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA. 3. Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Departments of Medical Social Sciences and Psychiatry and Behavioral Sciences, Northwestern University, Chicago, IL. 5. Department of Medicine and Center for Clinical Cancer Genetics and Global Health, University of Chicago, Chicago, IL. 6. Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
BACKGROUND: The MD Anderson Symptom Inventory (MDASI) is a psychometrically validated patient-reported outcome measure that assesses the severity and impact of multiple symptoms related to cancer and its treatment and has the potential to guide treatment specific to patients with prostate cancer. Although the original MDASI validation study encompassed various cancer types, the instrument's psychometric properties have not been examined in a large homogeneous sample of patients with prostate cancer. PATIENTS AND METHODS: This study involved secondary analysis of data from the nationwide multicenter Eastern Cooperative Oncology Group (ECOG) SOAPP (Symptom Outcomes and Practice Patterns) study, which enrolled patients from 38 ECOG-affiliated institutions, including 6 academic centers and 32 community clinics. Data were used to establish the psychometric properties of the MDASI in a subsample of 320 patients with prostate cancer. The instrument was administered twice, approximately 1 month apart. RESULTS: The MDASI demonstrated good internal consistency and test-retest reliability (with Cronbach alphas of ≥ .84 and intraclass correlations of ≥ 0.76 for all subscales), strong ability to discriminate between clinically different patient groups (by performance status, tumor response, and disease stage), and high sensitivity in detecting symptom change (with respect to patient-reported quality of life [QOL] between the baseline and 1-month follow-up visits). CONCLUSION: The MDASI is a valid, reliable, and sensitive symptom-assessment instrument that can be used with confidence in descriptive and clinical studies of symptom status in patients with prostate cancer.
BACKGROUND: The MD Anderson Symptom Inventory (MDASI) is a psychometrically validated patient-reported outcome measure that assesses the severity and impact of multiple symptoms related to cancer and its treatment and has the potential to guide treatment specific to patients with prostate cancer. Although the original MDASI validation study encompassed various cancer types, the instrument's psychometric properties have not been examined in a large homogeneous sample of patients with prostate cancer. PATIENTS AND METHODS: This study involved secondary analysis of data from the nationwide multicenter Eastern Cooperative Oncology Group (ECOG) SOAPP (Symptom Outcomes and Practice Patterns) study, which enrolled patients from 38 ECOG-affiliated institutions, including 6 academic centers and 32 community clinics. Data were used to establish the psychometric properties of the MDASI in a subsample of 320 patients with prostate cancer. The instrument was administered twice, approximately 1 month apart. RESULTS: The MDASI demonstrated good internal consistency and test-retest reliability (with Cronbach alphas of ≥ .84 and intraclass correlations of ≥ 0.76 for all subscales), strong ability to discriminate between clinically different patient groups (by performance status, tumor response, and disease stage), and high sensitivity in detecting symptom change (with respect to patient-reported quality of life [QOL] between the baseline and 1-month follow-up visits). CONCLUSION: The MDASI is a valid, reliable, and sensitive symptom-assessment instrument that can be used with confidence in descriptive and clinical studies of symptom status in patients with prostate cancer.
Authors: Carolyn Miller Reilly; Deborah Watkins Bruner; Sandra A Mitchell; Lori M Minasian; Ethan Basch; Amylou C Dueck; David Cella; Bryce B Reeve Journal: Support Care Cancer Date: 2013-01-12 Impact factor: 3.603
Authors: T S Armstrong; T Mendoza; I Gning; I Gring; C Coco; M Z Cohen; L Eriksen; Ming-Ann Hsu; M R Gilbert; C Cleeland Journal: J Neurooncol Date: 2006-04-06 Impact factor: 4.130
Authors: Ethan Basch; Amy P Abernethy; C Daniel Mullins; Bryce B Reeve; Mary Lou Smith; Stephen Joel Coons; Jeff Sloan; Keith Wenzel; Cynthia Chauhan; Wayland Eppard; Elizabeth S Frank; Joseph Lipscomb; Stephen A Raymond; Merianne Spencer; Sean Tunis Journal: J Clin Oncol Date: 2012-10-15 Impact factor: 44.544
Authors: Thomas M Atkinson; Charissa F Andreotti; Kailey E Roberts; Rebecca M Saracino; Marisol Hernandez; Ethan Basch Journal: Support Care Cancer Date: 2015-08-28 Impact factor: 3.603
Authors: Julia E Inglis; Michelle C Janelsins; Eva Culakova; Karen M Mustian; Po-Ju Lin; Ian R Kleckner; Luke J Peppone Journal: Support Care Cancer Date: 2019-07-02 Impact factor: 3.603
Authors: Angeles A Secord; Robert L Coleman; Laura J Havrilesky; Amy P Abernethy; Gregory P Samsa; David Cella Journal: Nat Rev Clin Oncol Date: 2015-03-10 Impact factor: 66.675
Authors: Nina Shah; Qiuling Shi; Sergio Giralt; Loretta Williams; Qaiser Bashir; Muzaffar Qazilbash; Richard E Champlin; Charles S Cleeland; Xin Shelley Wang Journal: Qual Life Res Date: 2017-12-19 Impact factor: 4.147
Authors: Loretta A Williams; Meagan S Whisenant; Tito R Mendoza; Shireen Haq; Karen N Keating; Brian Cuffel; Charles S Cleeland Journal: Qual Life Res Date: 2018-09-05 Impact factor: 4.147
Authors: Joleen M Hubbard; Axel F Grothey; Robert R McWilliams; Jan C Buckner; Jeff A Sloan Journal: J Oncol Pract Date: 2014-03-25 Impact factor: 3.840
Authors: Julia E Inglis; Amber S Kleckner; Po-Ju Lin; Nikesha J Gilmore; Eva Culakova; Amy C VanderWoude; Karen M Mustian; I Diana Fernandez; Richard F Dunne; Jeremy Deutsch; Luke J Peppone Journal: Nutr Cancer Date: 2020-08-19 Impact factor: 2.900